Understanding Peptide Purity: What 99% Does and Doesn’t Tell You

Purity is the number most people look for first on a certificate of analysis, and it is the most misread. A figure of 99.2 percent looks like a statement that 99.2 percent of whatever is in the vial is the peptide named on the label. It is not. It is the result of one analytical method, reversed-phase HPLC, answering one narrow question: of the material that absorbs ultraviolet light and elutes from the column, what fraction is the intended sequence? That question is important, and the answer is meaningful, but it leaves several other questions untouched. This note explains how the number is generated, what it includes and excludes, why two certificates can report different purities for the same material, and how to read the figure alongside the rest of a certificate of analysis.

How the purity number is produced

A small sample of the peptide is dissolved, injected onto a reversed-phase HPLC column and eluted with a gradient of water and acetonitrile, usually with 0.1 percent trifluoroacetic acid. Components separate according to hydrophobicity: more polar species elute early, more hydrophobic species late. As each emerges, a detector measures its absorbance at a chosen wavelength, typically 214 or 220 nm where the peptide backbone absorbs, producing a chromatogram of peaks against time. Software integrates the area under every peak. Purity is the area of the main peak divided by the total area of all peaks, expressed as a percentage.^1,2 Our companion note on HPLC describes the technique itself.

Three assumptions sit inside this calculation. First, that every impurity of interest absorbs at the detection wavelength roughly as strongly, per unit mass, as the target peptide. This is approximately true for sequence-related impurities, which share the same backbone, and false for anything without a peptide bond. Second, that the impurities actually separate from the main peak; a species that co-elutes is counted as product. Third, that everything injected comes off the column; material that adsorbs irreversibly or precipitates is invisible.²

What purity counts

The impurities that appear as separate peaks are, for the most part, the by-products of solid-phase synthesis and of subsequent storage. The analytical literature catalogues them in detail.^2,3 Deletion sequences lack one residue. Truncated sequences stopped growing partway through synthesis. Incompletely deprotected species retain a protecting group. Oxidized variants carry an extra oxygen on methionine, tryptophan or cysteine. Deamidated variants have converted an asparagine or glutamine to the corresponding acid. Aspartimide-derived isomers arise at aspartate residues during base treatment. Each of these is a peptide, closely related to the target, and each shows up as its own peak, usually within a few minutes of the main one. Purity is a summary of how well these were removed during preparative purification.

The figure is therefore best understood as a relative measure of sequence fidelity. A 99 percent purity means that 1 percent of the peptide-like material is something other than the intended sequence. It is a real and useful statement about the quality of synthesis and purification.

What purity does not count

A lyophilized peptide is not pure peptide by mass, and HPLC purity does not claim it is. Several components of the powder are invisible to the method.

• Counter-ions. Peptides purified with TFA in the mobile phase come out as trifluoroacetate salts. Every positively charged site (lysine, arginine, histidine and the N-terminus) carries a TFA anion. For a basic peptide this can amount to 10 to 30 percent of the dry weight. TFA has no chromophore at 214 nm and does not appear in the chromatogram.⁴
• Water. Lyophilized peptides are hygroscopic and typically retain several percent water even when handled carefully.
• Inorganic salts. Residual buffer components from purification or lyophilization.
• Non-absorbing organics. Residual solvents and scavengers from cleavage.

Taken together, these mean that a vial labeled as containing 10 mg of a 99 percent pure peptide typically contains between 6 and 8.5 mg of actual peptide. The measurement that captures this is net peptide content, determined by amino acid analysis, nitrogen determination or quantitative UV spectroscopy, and it is a separate line on a thorough certificate.^5,6 Our planned note on net peptide content versus purity treats this in detail. The two numbers answer different questions and neither substitutes for the other.

Question	Measurement	Typical method	Answered by purity?
What fraction of the peptide-like material is the right sequence?	Purity	RP-HPLC, UV 214–220 nm	Yes
Is the main peak actually the intended molecule?	Identity	Mass spectrometry (ESI or MALDI)	No
How much peptide is in the vial by weight?	Net peptide content	Amino acid analysis, nitrogen, quantitative UV	No
What counter-ion is present and how much?	Counter-ion content	Ion chromatography, 19F NMR	No
Is the material free of bacterial endotoxin?	Endotoxin	LAL or recombinant factor C assay	No
Is the material sterile?	Sterility	Culture-based sterility test	No
Does the peptide do what it should in an assay?	Activity	Receptor binding, cell assay	No

Purity tells you how clean the peptide is relative to its own mistakes; it does not tell you how much peptide you have, or that it is the peptide you ordered.

Identity is a separate question

A chromatogram with a single sharp peak proves only that the sample is homogeneous by the criterion the column applies. It does not prove that the peak is the intended peptide. Mass spectrometry answers that question by measuring the molecular weight of the main component and comparing it with the value calculated from the sequence. A match within a fraction of a dalton is strong evidence of identity; a mismatch of 16 (oxidation), 1 (deamidation) or the mass of a residue (deletion) identifies the problem.² Our planned note on mass spectrometry explains the technique. A certificate that reports purity without an accompanying mass result has confirmed cleanliness but not identity.

Even mass spectrometry has a blind spot. A peptide in which one L-amino acid has been replaced by its D-enantiomer during synthesis has exactly the same mass as the target. Only chromatography can separate the two, and only if the method has been developed to do so. This is one reason purity and identity are reported together rather than either alone.²

Why the same lot can show different numbers

Purity is method-dependent, and a certificate should state the method. Several factors move the figure.

Wavelength. At 214 nm every peptide bond absorbs, so all sequence-related impurities are visible. At 254 or 280 nm only aromatic side chains absorb, so impurities lacking tryptophan, tyrosine or phenylalanine may disappear from the chromatogram and purity will read higher. A purity reported at 280 nm for a peptide with few aromatic residues is less informative than one reported at 214 nm.¹

Gradient and column. A steep gradient compresses peaks and may merge a close-eluting impurity into the main peak. A shallow gradient on a high-resolution column separates more species and generally reports a lower, more honest purity. Two laboratories using different methods on the same material can legitimately report figures a percentage point or more apart.^1,7

Integration parameters. Where the baseline is drawn and how small a peak must be before it is counted affect the total. Pharmaceutical practice sets a reporting threshold below which peaks are disregarded; for small-molecule drug substances ICH Q3A places it at 0.05 percent, although that guideline explicitly excludes peptides from its scope.⁸

Sample age and handling. Purity is a property of a lot at the time of testing. A peptide stored in solution, or exposed to light, oxygen or moisture, will show new oxidation and deamidation peaks over time. A certificate dated at manufacture does not describe a vial that has been reconstituted and kept for weeks.

What the pharmaceutical standards say

Research-grade peptides are not subject to pharmaceutical specifications, but those specifications are the best available reference for what a rigorous purity assessment looks like. The United States Pharmacopeia’s general chapter <1503> on quality attributes of synthetic peptide drug substances describes the impurity classes expected from solid-phase synthesis and the orthogonal methods needed to control them.⁹ FDA’s 2021 guidance on synthetic versions of certain recombinant-origin peptides requires that every peptide-related impurity at or above 0.10 percent be identified, and that any new impurity not present in the reference product be held at or below 0.5 percent and justified.¹⁰ Reviews of regulatory expectations for peptide drugs recommend combining reversed-phase HPLC with a second, orthogonal separation and with mass spectrometry, because no single method sees everything.^3,7

Against that backdrop, a research-grade certificate reporting HPLC purity, mass-spectrometric identity and, ideally, net peptide content is doing most of what a pharmaceutical certificate does for the questions a laboratory researcher needs answered. What it typically does not do is characterize each impurity individually, control counter-ion content, or test for sterility and endotoxin, and a reader should not assume those tests were performed unless they are reported.

Why the impurity fraction matters in research

A one percent impurity fraction sounds negligible, and for many experiments it is. But sequence-related impurities are not inert filler. A deletion sequence may bind the same receptor with different affinity, or antagonize it. An oxidized methionine can change conformation. Trifluoroacetate, though not a peptide impurity, has been shown to affect proliferation in cultured osteoblasts and chondrocytes at concentrations that can occur when TFA-salt peptides are used in cell culture, which is one reason some experimental protocols specify counter-ion exchange.¹¹ In pharmaceutical development the concern is immunogenicity: impurities that are recognized as foreign can provoke antibody responses in ways the parent peptide does not, which is why FDA sets the thresholds described above.¹⁰ For the laboratory researcher, the practical lesson is that the identity of the impurities can matter as much as their total, and that a chromatogram showing where the minor peaks fall relative to the main one carries information the summary percentage does not.

Reading the number in context

Purity is a good number when it is read as what it is: a chromatographic measure of sequence fidelity, produced by a stated method, for a specific lot, at a specific time. It is the first thing to look for on a certificate and the wrong thing to stop at. Wednesday’s COA library publishes HPLC chromatograms and mass spectra together for each lot so that the two questions, how clean and what is it, can be answered side by side. The planned note on how to read a certificate of analysis walks through a full document line by line.

Frequently asked questions

What does 99% purity mean for a peptide?

It means that in an HPLC analysis, 99 percent of the total UV-absorbing peak area belonged to the target peptide and 1 percent to closely related sequence impurities such as deletion, truncated or oxidized variants. It does not mean 99 percent of the powder by weight is peptide, because water, counter-ions and salts are not detected by the method.

Is 98% peptide purity good?

For most laboratory research purposes, purity in the range of 95 to 99 percent by HPLC is standard, and the difference between 98 and 99 is usually less important than whether a mass spectrum confirms identity and whether the certificate applies to the specific lot. Pharmaceutical specifications are stricter and require each impurity above 0.1 percent to be identified.

What is the difference between peptide purity and peptide content?

Purity is the fraction of peptide-related material that is the correct sequence, measured by HPLC. Net peptide content is the fraction of the total powder weight that is peptide, measured by amino acid analysis or similar methods, and it accounts for water and counter-ions. A 99 percent pure peptide commonly has a net content of 60 to 85 percent.

Can peptide purity be 100%?

Not in practice. Every synthesis produces some sequence-related by-products, and purification removes most but not all of them. A reported purity of 100 percent usually reflects a method that failed to separate the impurities or a detection wavelength at which they were invisible, rather than a genuinely impurity-free sample.

How is peptide purity tested?

By reversed-phase high-performance liquid chromatography. The peptide is separated from its impurities on a column, each component is detected by UV absorbance, and the area of the main peak is divided by the total peak area. Mass spectrometry is run alongside to confirm that the main peak has the molecular weight of the intended sequence.

References & further reading

1. Mant CT, Chen Y, Yan Z, et al. HPLC analysis and purification of peptides. Methods Mol Biol. 2007;386:3-55. doi:10.1007/978-1-59745-430-8_1 / PMID 18604941
2. D’Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. doi:10.1016/j.jpba.2014.06.012 / PMID 25044089
3. Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. doi:10.1002/psc.1167
4. Roux S, Zékri E, Rousseau B, Paternostre M, Cintrat JC, Fay N. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J Pept Sci. 2008;14(3):354-359. doi:10.1002/psc.951 / PMID 18035848
5. Rutherfurd SM, Gilani GS. Amino acid analysis. Curr Protoc Protein Sci. 2009;58:11.9.1-11.9.37. doi:10.1002/0471140864.ps1109s58 / PMID 19937719
6. Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27. doi:10.1002/psc.2836 / PMID 26785684
7. Fekete S, Veuthey JL, Guillarme D. New trends in reversed-phase liquid chromatographic separations of therapeutic peptides and proteins: theory and applications. J Pharm Biomed Anal. 2012;69:9-27. doi:10.1016/j.jpba.2012.03.024 / PMID 22475515
8. International Council for Harmonisation. Impurities in New Drug Substances Q3A(R2). October 2006. database.ich.org
9. United States Pharmacopeia. General Chapter <1503> Quality Attributes of Synthetic Peptide Drug Substances. USP-NF. doi.usp.org
10. US Food and Drug Administration. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin: Guidance for Industry. May 2021. fda.gov
11. Cornish J, Callon KE, Lin CQ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-E783. doi:10.1152/ajpendo.1999.277.5.E779 / PMID 10567002